These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 4784941)

  • 1. Metabolic interactions of pyridoxine, levodopa, and carbidopa in Parkinson's disease.
    Mars H
    Trans Am Neurol Assoc; 1973; 98():241-5. PubMed ID: 4784941
    [No Abstract]   [Full Text] [Related]  

  • 2. Levodopa, carbidopa, and pyridoxine in Parkinson disease. Metabolic interactions.
    Mars H
    Arch Neurol; 1974 Jun; 30(6):444-7. PubMed ID: 4827061
    [No Abstract]   [Full Text] [Related]  

  • 3. L-Dopa, B 6 , and alpha-methyldopa hydrazine.
    Klawans HL; Ringel SP
    Confin Neurol; 1973; 35(3):186-92. PubMed ID: 4712885
    [No Abstract]   [Full Text] [Related]  

  • 4. [Effect of MK-486 alone on Parkinsonism; studies on the clinical symptoms and catecholamine concentrations in the blood, urine and cerebrospinal fluid].
    Tohgi H; Ogawa M
    No To Shinkei; 1977 Feb; 29(2):205-13. PubMed ID: 326277
    [No Abstract]   [Full Text] [Related]  

  • 5. Parkinson's disease: from brain homogenate to treatment.
    Hornykiewicz O
    Fed Proc; 1973 Feb; 32(2):183-90. PubMed ID: 4143953
    [No Abstract]   [Full Text] [Related]  

  • 6. "On-off" phenomenon with levodopa therapy in Parkinsonism. Clinical and pharmacologic correlations and the effect of intramuscular pyridoxine.
    Fahn S
    Neurology; 1974 May; 24(5):431-41. PubMed ID: 4857104
    [No Abstract]   [Full Text] [Related]  

  • 7. Dopaminergic nervous transmission in Parkinson's disease.
    Rinne UK; Sonninen V; Riekkinen P; Laaksonen H
    Med Biol; 1974 Jun; 52(3):208-17. PubMed ID: 4371255
    [No Abstract]   [Full Text] [Related]  

  • 8. [Combined treatment of Parkinsonism with L-dopa and peripheral dopa decarboxylase inhibitors--clinical course of 13 cases and levels of serum/dopa and dopamine].
    Mizuno Y; Yoshida M; Obayashi T; Ueki A
    Rinsho Shinkeigaku; 1976 Jul; 16(7):511-9. PubMed ID: 986921
    [No Abstract]   [Full Text] [Related]  

  • 9. [Abnormal movements induced by L-Dopa and dopamine metabolism disorders].
    Lhermitte F; Rosa A; Comoy E; Bohuon C
    Rev Neurol (Paris); 1973 Dec; 129(6):313-24. PubMed ID: 4794176
    [No Abstract]   [Full Text] [Related]  

  • 10. [Decarboxylase inhibitors combined with L-dopa in the treatment of Parkinson's disease].
    Rondot P
    Rev Prat; 1974 Mar; 24(15):1211-2, 1215-6, 1219. PubMed ID: 4416964
    [No Abstract]   [Full Text] [Related]  

  • 11. [L-DOPA with the decarboxylase inhibitor Ro 4-4602 in the treatment of Parkinson's disease].
    Lakke JP; Nienhuis RJ; Meyer R; Zwols F; Schut T
    Ned Tijdschr Geneeskd; 1972 Nov; 116(48):2180-4. PubMed ID: 4639072
    [No Abstract]   [Full Text] [Related]  

  • 12. Recent advances in the treatment of Parkinson's disease.
    Martocci RJ
    J Am Osteopath Assoc; 1975 Apr; 74(8):730-41. PubMed ID: 1092751
    [No Abstract]   [Full Text] [Related]  

  • 13. Levodopa and dopamine in cerebrospinal fluid.
    Papavasiliou PS; Cotzias GC; Lawrence WH
    Neurology; 1973 Jul; 23(7):756-9. PubMed ID: 4736493
    [No Abstract]   [Full Text] [Related]  

  • 14. [Symposium: metabolism in neurological disorders. 1. Parkinsonism. 1-(2). Dopamin metabolism in urine and brain of patients with parkinsonism, with special reference to vitamin B 6 and L-DOPA-treatment].
    Kuzuya F; Wakita T; Kawahara H
    Nihon Naika Gakkai Zasshi; 1972 Sep; 61(9):1131-5. PubMed ID: 4674039
    [No Abstract]   [Full Text] [Related]  

  • 15. Treatment of Parkinson's disease with carbidopa, a peripheral decarboxylase inhibitor, and levodopa.
    Fermaglich J
    Med Ann Dist Columbia; 1974 Dec; 43(12):587-91. PubMed ID: 4532167
    [No Abstract]   [Full Text] [Related]  

  • 16. Failure of vitamin B6 to reverse the L-dopa effect in patients on a dopa decarboxylase inhibitor.
    Klawans HL; Ringel SP; Shenker DM
    J Neurol Neurosurg Psychiatry; 1971 Dec; 34(6):682-6. PubMed ID: 5158783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural insight into Parkinson's disease treatment from drug-inhibited DOPA decarboxylase.
    Burkhard P; Dominici P; Borri-Voltattorni C; Jansonius JN; Malashkevich VN
    Nat Struct Biol; 2001 Nov; 8(11):963-7. PubMed ID: 11685243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. L-dopa therapy in parkinsonism: mechanism of action.
    Sandler M
    Psychiatr Neurol Neurochir; 1971; 74(4):331-3. PubMed ID: 5146239
    [No Abstract]   [Full Text] [Related]  

  • 19. Amino acid and dopa levels in plasma and urine from L-dopa-treated patients with Parkinson's disease.
    Hare TA; Vanna S; Beasley B; Chambers R; Vogel WH
    J Lab Clin Med; 1971 Feb; 77(2):319-25. PubMed ID: 5540775
    [No Abstract]   [Full Text] [Related]  

  • 20. MAO and L-dopa treatment of Parkinson's disease.
    Tyce GM; Dousa MK; Muenter MD
    J Neural Transm Suppl; 1990; 29():233-9. PubMed ID: 2358803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.